Pluristem CEO Zami Aberman Elected to Board of Directors of the Alliance for Regenerative Medicine Print
Wednesday, 07 October 2015 18:24

HAIFA, Israel, Oct. 07, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (PSTI), a leading developer of placenta-based cell therapy products, today announced that Pluristem’s Chairman and CEO, Zami Aberman, has been elected to serve on the Board of Directors of the Alliance for Regenerative Medicine (ARM). Based in Washington, D.C., ARM promotes research, development, investment and commercialization of regenerative medicine technologies. Pluristem has been a member of ARM for 3 years and has actively supported the organization’s goals. Mr. Aberman joins other prominent leaders in the field of regenerative medicine who are currently serving on the board.

    

Dr. Karine Kleinhaus, Divisional Vice President, North America, will present at 10:45 a.m. on October 7 at the Stem Cell Meeting on the Mesa to be held October 7-9, 2015 in La Jolla, California. Co-hosted by ARM, the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2015 Stem Cell Meeting on the Mesa is attended by leading cell therapy, gene therapy and tissue engineering companies, large pharma and biotech, industry investors and major academic research institutions. A live video webcast of the presentation will be available at:http://stemcellmeetingonthemesa.com/webcast/ and will also be published on ARM’s website shortly after the event.

   

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company has reported robust clinical trial data in multiple indications for its patented PLX (PLacental eXpanded) cells. The cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cell products are grown using the Company's proprietary three-dimensional expansion technology. They are off-the-shelf, requiring no tissue matching prior to administration.

Pluristem has a strong intellectual property position; Company-owned, GMP-certified manufacturing and

research facilities; strategic relationships with major research institutions; and a seasoned management team.




BiomedReports is not paid or compensated by newswires to disseminate or report news and

Error. Page cannot be displayed. Please contact your service provider for more details. (26)

developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and
investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
  BMR:1